WASHINGTON, D.C. – As tensions escalate with nuclear powers such as Russia, the administration of President Joe Biden has reportedly spent approximately $290 million into purchases of anti-radiation drugs in the event of a potential nuclear conflict, as per a press release put out by the Department of Health and Human Services (HSS).
The press release, which can be read in its entirety here, outlines the HSS’ purchase of large stocks of the medication Nplate, which is used to treat damage to human cells acquired from radiation exposure.
As part of long-standing, ongoing efforts to be better prepared to save lives following radiological and nuclear emergencies, the U.S. Department of Health and Human Services is purchasing a supply of the drug Nplate from Amgen USA Inc; Nplate is approved to treat blood cell injuries that accompany acute radiation syndrome in adult and pediatric patients (ARS).
The HSS purchase comes amid rising conflict between the United States and Russia due to the ongoing war in Ukraine, with fears mounting that Russian President Vladimir Putin may resort to nuclear weapons to counter his losses in that conflict after making general threats to do so if Russia is attacked. According to Newsweek, such a move would likely be considered his last resort.
In turn, the United States has promised “catastrophic consequences” if Putin used nuclear weapons; however, President Biden refrained from commenting when asked about those potential consequences during an interview on Wednesday.
Approximately three months ago in July, the New York City Emergency Management department shared important steps for New Yorkers to follow if a nuclear attack occurs. While many worried at the time why the PSA was released, an account labeled as the Defcon Warning System, said on Twitter, that the release was not in response to any specific threat.”
or a specific category with our 
Comments are closed.